Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii
Status:
Unknown status
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus
inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline
solution in patients with VAP due to baumannii carbapenems resistant.